Stock listing
TCRX Stock Price, News, Filings & Events — Tscan Therapeutics, Inc.
Selected listing: TCRX · BOATS · USD · US
This page tracks Tscan Therapeutics, Inc.'s TCRX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following TCRX:BOATS. TCRX:BOATS is the stock-level entry point for investors researching Tscan Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Tscan Therapeutics, Inc. is a public company traded under the ticker TCRX in the American market. The company has a market capitalization of approximately $51.9 million. Tscan focuses on developing innovative therapies for cancer and other diseases through its proprietary T-cell receptor platform.

- Ticker
- TCRX:BOATS
- Asset type
- Stock
- Market cap
- $21.7M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Tscan Therapeutics, Inc. TCRX:BOATS stock context
This page tracks Tscan Therapeutics, Inc.'s TCRX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following TCRX:BOATS. TCRX:BOATS is the stock-level entry point for investors researching Tscan Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Tscan Therapeutics, Inc. is a public company traded under the ticker TCRX in the American market. The company has a market capitalization of approximately $51.9 million. Tscan focuses on developing innovative therapies for cancer and other diseases through its proprietary T-cell receptor platform.
Latest news from Tscan Therapeutics, Inc.
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 2, 2026
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 30, 2026
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026
Research Tscan Therapeutics, Inc.
Tscan Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for TCRX:BOATS.
Tscan Therapeutics, Inc. company profile
View the public company page for Tscan Therapeutics, Inc. on 6ix.
Tscan Therapeutics, Inc. news
Read company news and market updates connected to Tscan Therapeutics, Inc..
Tscan Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Tscan Therapeutics, Inc..